Dr. Reddy’s Laboratories’ profit fell in the second quarter of fiscal 2025, missing analysts’ estimates. The bottom line of the pharmaceutical company declined 9% year-on-year to Rs 1,341.90 crore in the quarter ended Sept. 30, 2024, according to an exchange filing on Nov. 5. That compares with the Rs 1,427-crore estimate that analysts tracked by Bloomberg had projected.
“Dr. Reddy’s Laboratories Ltd. sees its overall sales growing in double-digits and is working towards delivering both Ebitda and return-on-capital of 25% on a consistent basis,” according to Chief Executive Officer of Branded Markets India and Emerging Markets, MV Ramana.
“We are in a pretty healthy space as far as the margins are concerned,” Ramana told NDTV Profit’s Sajeet Manghat in a post-earnings interview. “We would be able to work towards delivering an Ebitda of about 25% and an ROC of 25% on a consistent basis.”
